NBIO: AI 评分 42/100 — AI 分析 (4月 2026)

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for cancer treatment. Their lead drug, Pritumumab, targets brain cancer malignancies and epithelial cancers, while their MultiPharm platform aims to address cancer, diabetes, autoimmunity, and transplantation.

Key Facts: AI Score: 42/100 Sector: Healthcare

公司概况

概要：

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in monoclonal antibody development for cancer therapies, including Pritumumab for brain and epithelial cancers. The company's MultiPharm platform expands its focus to diabetes, autoimmunity, and transplantation, positioning it within the competitive biotechnology landscape.

NBIO是做什么的？

Nascent Biotech, Inc., based in Vero Beach, Florida, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative monoclonal antibody therapies for various forms of cancer. The company's primary focus is on Pritumumab, a drug designed to treat patients suffering from brain cancer malignancies such as glioblastoma and malignant astrocytoma. Pritumumab also targets epithelial cancers, including lung, breast, colon, brain, and pancreas cancer, representing a broad therapeutic potential. In addition to Pritumumab, Nascent Biotech is developing MultiPharm, a proprietary technology platform aimed at cancer therapy, as well as addressing other significant health challenges like diabetes, autoimmunity, and transplantation. While the company's founding story and early evolution details are not available, its current strategy centers on advancing Pritumumab through clinical trials and further developing the MultiPharm platform. Nascent Biotech operates within the highly competitive biotechnology sector, striving to differentiate itself through its targeted approach to cancer treatment and its broader ambitions with the MultiPharm platform. The company's success hinges on the successful completion of clinical trials, regulatory approvals, and effective commercialization of its therapies.

NBIO的投资论点是什么？

Nascent Biotech, Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biopharmaceutical companies. The primary value driver is the successful development and commercialization of Pritumumab, targeting a significant unmet need in brain and epithelial cancer treatment. Positive clinical trial results for Pritumumab would serve as a major catalyst, potentially leading to significant stock appreciation. The MultiPharm platform offers additional long-term potential, expanding the company's therapeutic scope beyond cancer. However, the company's reliance on OTC markets and limited financial information increase the investment risk. The company's negative P/E ratio of -0.02 reflects its current lack of profitability. Investors should carefully assess the risks associated with clinical-stage biotech companies and the uncertainties of OTC trading.

NBIO在哪个行业运营？

Nascent Biotech operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The industry is driven by innovation and the constant pursuit of new treatments for diseases with unmet needs. Nascent Biotech's focus on monoclonal antibodies for cancer treatment aligns with a major trend in the industry, as these therapies have shown promise in targeting cancer cells with greater precision. Competitors like BSYI, CHNXF, CWWBF, FCHS, and PZOO also operate in the biotechnology space, developing various therapies and technologies.

Biotechnology

Healthcare

NBIO有哪些增长机遇？

Advancement of Pritumumab: The successful completion of clinical trials for Pritumumab and subsequent regulatory approval represent a significant growth opportunity for Nascent Biotech. The market for brain cancer therapies is substantial, with a growing need for more effective treatments. Positive clinical data could lead to partnerships with larger pharmaceutical companies for commercialization, providing a significant revenue stream. The timeline for this growth opportunity depends on the progress of clinical trials and regulatory review processes.
Expansion of MultiPharm Platform: The MultiPharm platform offers a broader growth opportunity by extending the company's focus beyond cancer to include diabetes, autoimmunity, and transplantation. These are large and growing markets with significant unmet needs. Successful development of therapies using the MultiPharm platform could diversify the company's revenue streams and reduce its reliance on Pritumumab. The timeline for this growth opportunity is longer-term, as it requires further research and development.
Strategic Partnerships and Collaborations: Forming strategic partnerships with other biotechnology or pharmaceutical companies can accelerate the development and commercialization of Nascent Biotech's therapies. Collaborations can provide access to additional funding, expertise, and resources. These partnerships can also expand the company's market reach and increase its visibility within the industry. The timing of these partnerships is uncertain but could occur at any stage of development.
Expansion into New Geographic Markets: While the company is based in the US, expanding into new geographic markets, such as Europe or Asia, could increase its potential customer base and revenue. This expansion would require navigating different regulatory environments and establishing distribution networks. The timeline for this growth opportunity depends on the company's resources and strategic priorities.
Acquisition or Merger: Nascent Biotech could be acquired by a larger pharmaceutical company seeking to expand its portfolio of cancer therapies. An acquisition would provide a significant return to investors. Alternatively, Nascent Biotech could merge with another biotechnology company to create a larger, more diversified entity. The timing of an acquisition or merger is uncertain and depends on market conditions and the company's performance.

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for cancer treatment.
The company's lead drug, Pritumumab, targets brain cancer malignancies and epithelial cancers.
MultiPharm, a proprietary technology platform, aims to address cancer, diabetes, autoimmunity, and transplantation.
The company is based in Vero Beach, Florida.
The company's stock trades on the OTC market.

NBIO提供哪些产品和服务？

Develop monoclonal antibody therapies for cancer treatment.
Focus on Pritumumab, a drug targeting brain cancer malignancies and epithelial cancers.
Develop the MultiPharm platform for cancer therapy, diabetes, autoimmunity, and transplantation.
Conduct clinical trials to evaluate the safety and efficacy of their therapies.
Seek regulatory approval from agencies like the FDA.
Potentially partner with larger pharmaceutical companies for commercialization.

NBIO如何赚钱？

Develop and patent novel monoclonal antibody therapies.
Conduct clinical trials to demonstrate efficacy and safety.
Seek regulatory approval for commercialization.
Out-license or partner with larger pharmaceutical companies for manufacturing and distribution.

Patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma.
Patients with epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Potentially, patients with diabetes, autoimmune diseases, and those requiring transplantation (through MultiPharm platform).

Proprietary technology platform (MultiPharm).
Patents protecting their monoclonal antibody therapies.
Clinical data supporting the efficacy and safety of Pritumumab.
Expertise in developing monoclonal antibody therapies.

什么因素可能推动NBIO股价上涨？

Upcoming: Announcement of clinical trial results for Pritumumab.
Upcoming: Potential strategic partnerships with larger pharmaceutical companies.
Ongoing: Development of new therapies using the MultiPharm platform.

NBIO的主要风险是什么？

Potential: Failure to obtain regulatory approval for Pritumumab.
Ongoing: Competition from other biotechnology and pharmaceutical companies.
Potential: Difficulty raising capital.
Ongoing: Limited financial resources.
Ongoing: Trading on the OTC market.

NBIO的核心优势是什么？

Proprietary technology platform (MultiPharm).
Targeted approach to cancer treatment with Pritumumab.
Potential to expand into other therapeutic areas (diabetes, autoimmunity, transplantation).
Experienced leadership team.

NBIO的劣势是什么？

Clinical-stage company with no approved products.
Reliance on successful development and commercialization of Pritumumab.
Limited financial resources.
Trading on the OTC market.

NBIO有哪些机遇？

Positive clinical trial results for Pritumumab.
Strategic partnerships with larger pharmaceutical companies.
Expansion into new geographic markets.
Development of new therapies using the MultiPharm platform.

NBIO面临哪些威胁？

Failure to obtain regulatory approval for Pritumumab.
Competition from other biotechnology and pharmaceutical companies.
Unfavorable changes in the regulatory environment.
Difficulty raising capital.

NBIO的竞争对手是谁？

BeyondSpring Inc. — Focuses on cancer therapies and immuno-oncology. — (BSYI)
Pharma Resources Group Inc. — Unknown differentiation based on available data. — (CHNXF)
Cannawide Swiss Ag — Unknown differentiation based on available data. — (CWWBF)
First Choice Healthcare Solutions Inc. — Unknown differentiation based on available data. — (FCHS)
Cornerstone Total Return Fund Inc. — Unknown differentiation based on available data. — (PZOO)

Key Metrics

MoonshotScore: 42/100

Company Profile

CEO: Sean Carrick
Headquarters: Vero Beach, US
Founded: 2009

AI Insight

AI analysis pending for NBIO

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Nascent Biotech, Inc. do?

Nascent Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for the treatment of various forms of cancer. Their lead drug candidate, Pritumumab, targets brain cancer malignancies and epithelial cancers. Additionally, they are developing the MultiPharm platform, which aims to address cancer, diabetes, autoimmunity, and transplantation. As a clinical-stage company, they are currently focused on advancing their drug candidates through clinical trials and seeking regulatory approvals.

What do analysts say about NBIO stock?

As of 2026-03-15, formal analyst ratings and price targets for Nascent Biotech (NBIO) are unavailable, likely due to its OTC market listing and small market capitalization. The company's valuation is influenced by the potential success of Pritumumab and the MultiPharm platform. Investors should conduct their own due diligence and consider the inherent risks associated with clinical-stage biotechnology companies and OTC-listed stocks.

What are the main risks for NBIO?

Nascent Biotech faces several key risks inherent to clinical-stage biotechnology companies. These include the risk of failure to obtain regulatory approval for Pritumumab, competition from other companies developing cancer therapies, the need for significant capital to fund research and development, and the risks associated with trading on the OTC market, such as low liquidity and limited financial disclosure. These factors contribute to the high-risk nature of investing in NBIO.